among other areas. From July 2017 until the closing of the Combination, Mr. Roman was Mylans Global General Counsel, with similar responsibilities. Prior to 2017, Mr. Roman served
as Mylans Chief Administrative Officer from January 2016 until June 2017, with responsibility for oversight of the Human Relations, Compliance, Facilities, Security, Information Security, and Privacy functions. He served as Mylans Senior
Vice President and Chief Compliance Officer from April 2010 until December 2015 and Vice President and General Counsel, North America from October 2005 until April 2010.
President, Japan, Australia, and New Zealand (JANZ). Mr. Cuneo has served as President, JANZ since the closing of the Combination on
November 16, 2020. His responsibilities include oversight of the day-to-day operations in the region. From April 2017 until the closing of the Combination,
Mr. Cuneo was Mylans PresidentRest of World, with responsibility for executing on commercial objectives in more than 120 countries, including developed and emerging markets. Mr. Cuneo joined Mylan in February 2009 and served as
Head of Global Business Development until April 2017. Previously, Mr. Cuneo served as Director of Merrill Lynchs Global Healthcare Investment Banking Group.
President, Developed Markets. Mr. Mauro has served as President, Developed Markets since the closing of the Combination on
November 16, 2020. His responsibilities include oversight of the commercial functions in more than 35 countries in North America and Europe, including sales and marketing strategies in those regions. From January 2016 until the closing of the
Combination, Mr. Mauro served as Chief Commercial Officer of Mylan, with responsibility for overseeing Mylans commercial businesses around the world. Prior to 2016, Mr. Mauro served as Mylans President, North America beginning
January 1, 2012. He served as President of Mylan Pharmaceuticals Inc. from 2009 through February 2013. Mr. Mauro previously served as Chief Operating Officer of Mylan Pharmaceuticals ULC in Canada, Vice President of North America Strategic
Development, and Vice President of North America Sales.
President, Greater China. Mr. Ni has served as President, Greater
China since the closing of the Combination on November 16, 2020. His responsibilities include oversight of day-to-day operations in the region and overseeing the
development and execution of the Companys strategy in Greater China. From March 2019 until the closing of the Combination, Mr. Ni served as Senior Vice President of Global Strategy, Business Development, and Commercial Development at
Pfizers Upjohn division, with responsibility for corporate strategy, business development, global marketing, pricing and channel management, commercial operations, and commercial excellence. He was Head of Established Brands, Global Product
and Portfolio Strategy with AstraZeneca from July 2017 until February 2019, with responsibility for the global established brands portfolio based in the U.S. Prior to that, he was Vice President of Alliances and Business Development for AstraZeneca
China from April 2014 until July 2017 and Executive Director, Strategic Planning and Business Development from February 2013 to April 2014.
President, Emerging Markets. Mr. Taddese has served as President, Emerging Markets since the closing of the Combination on November 16, 2020. His responsibilities include oversight of
day-to-day operations in the segment, including leading the segments commercial team and establishing and executing on the Companys strategy. From October
2018 until the closing of the Combination, Mr. Taddese served as Regional President, Emerging Markets at Pfizers Upjohn division, with commercial responsibility for the Upjohn Business across the segment. From December 2017 until October
2018, Mr. Taddese served as Regional President for Pfizers Essential Health business in Africa and the Middle East, with responsibility for Pfizers established portfolio business throughout the region. Prior to that role, he served
as Regional Lead and General Manager from January 2016 until November 2017, with responsibility for Pfizers Innovative Health Business in Africa and the Middle East. Previously, Mr. Taddese held a number of senior roles at Pfizer,
including Vice President, Chief Financial Officer, GIP North America from January 2014 until December 2015, and Vice President and Chief Financial Officer, US Primary Care from April 2011 to December 2013.
Pursuant to our Bylaws, officers hold office until their successors are chosen and qualify in their stead or until their earlier death, resignation
or removal.
Executive Chairman. Mr. Coury has served as Viatris Executive Chairman since the closing of the
Combination on November 16, 2020. Mr. Coury leads the Viatris Board, leads the strategic direction of the Company with the Board and in collaboration with executive management, advises the management team as they execute on the
Companys strategy to drive value creation, and leads Company strategy on highly complex and strategic initiatives, while also ensuring robust board engagement with shareholders and other key stakeholders, among other responsibilities.
Additional details regarding Mr. Courys background and experience can be found under the heading Viatris Board of Directors on page 15.
|
|
|
|
|
34 | 2021 Proxy Statement
|
|
|
|
|